Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.